Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs

Cancer Clinical Trial

— EVOLVE  

Official title:

A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01871519
• Other study ID #: P12-03
• Status: Completed
• Phase: N/A
• First received: June 4, 2013
• Last updated: November 2, 2016
• Start date: May 2013
• Est. completion date: May 2016

Study information

• Verified date: May 2016
• Source: Medtronic Spinal and Biologics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study objective is to collect and report 12-month outcomes pertaining to activities of daily living, quality of life, and safety parameters in a Medicare population to be treated with balloon kyphoplasty in the treatment of painful, acute, vertebral body compression fractures (VCFs) associated with either osteoporosis or cancer. The primary objective is to show statistically significant improvement from baseline in the four co-primary endpoints (SF-36v2, PCS, EQ-5D, NRS back pain and ODI) at 3-months; study success will be declared if the primary objective is met. New radiographic fractures, non-surgical management received, VCF-related healthcare resource utilization, and vertebral body height restoration data will also be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 354
• Est. completion date: May 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. Identified as an appropriate candidate for BKP and should have made the choice to have the procedure.

2. Must be Medicare Eligible (At least 65 years of age or otherwise eligible).

3. Must have one to three target VCFs, located between T5 and L5, which are due to underlying primary or secondary osteoporosis or cancer.

4. Cancer patients should not have had a change in chemotherapy regimen within the last month, nor should they have a planned change within the next month from time of enrollment, with the exception of changes in dose.

5. All VCFs to be treated must have clinical pain symptoms (pain on palpation/percussion over the fractured vertebral body) that correlate with radiographic findings as follows:

1. Height change: An acute (= four month) change in VB height or morphology from a previous x-ray, CT or MRI, with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of one or more grades by the Genant criteria20, OR

2. Positive MRI or bone scan: VB shows hyperintense signal on STIR sequence MRI, or target VB is positive on radionuclide bone scan.

6. All VCFs to be treated must have an estimated fracture age of four months or less.

7. Treatment of all target VCFs must be technically feasible and clinically appropriate for balloon kyphoplasty.

8. Pre-treatment back pain by numerical rating scale (NRS) score must be = 7 (0-10 scale) and refractory to non-surgical management.

9. Pre-treatment Oswestry Disability Index must be =30 (0 - 100 scale).

10. Must have life expectancy of = 12 months.

11. Must declare availability for all study visits.

12. Must be able to understand the risks and benefits of participating in the study and be willing to provide written informed consent.

13. Must have the mental capacity necessary to comply with protocol requirements for the 12- month duration of study.

Exclusion Criteria:

1. Vertebral body morphology or fracture configuration contraindicative of balloon kyphoplasty.

2. VCFs due to high-energy trauma.

3. Asymptomatic VCFs or prophylactic treatment of non-fractured vertebral bodies.

4. VCFs accompanied at the same site by primary tumors of the bone (e.g., osteosarcoma), solitary plasmacytoma or osteoblastic tumors.

5. Platelet count of <20,000/uL as measured at the time of hospital admission for the procedure.

6. Back pain due to causes other than acute fracture.

7. VCF with a clinically estimated (based on radiographic evidence as well as patient history) age of fracture > four months.

8. VCF accompanied by objective evidence of secondary radiculopathy or neurologic compromise.

9. VCFs with the need for spinal surgery beyond balloon kyphoplasty.

10. Spinal cord compression or canal compromise requiring decompression.

11. Significant clinical comorbidity that may either contra-indicate surgery or interfere with long-term data collection or follow-up.

12. Pre-existing conditions contrary to balloon kyphoplasty such as:

1. Allergy to any components (e.g., bone cement, contrast medium) of the balloon kyphoplasty device/procedure.

2. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection.

3. Irreversible coagulopathy or bleeding disorder.

13. Contraindications to both MRI and radionuclide bone scan.

14. Concurrent participation in another clinical study.

15. Pregnant or intending to become pregnant during the course of the study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer
• Compression Fracture of Vertebral Body
• Fractures, Bone
• Fractures, Compression
• Osteoporosis

Intervention

Device:
• Balloon kyphoplasty
The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.

Locations

Country	Name	City	State
United States	Alabama Clinical Therapeutics, LLC	Birmingham	Alabama
United States	University of Alabama at Birmingham, Division of Neurological Surgery	Birmingham	Alabama
United States	Physicians & Surgeons of Pocatello	Blackfoot	Idaho
United States	Central Illinois Neuroscience Foundation	Bloomington	Illinois
United States	St. Luke's Health System	Boise	Idaho
United States	Indiana Spine Group	Carmel	Indiana
United States	Clinical Investigations, LLC	Edmond	Oklahoma
United States	NeuroSpine Institute, LLC	Eugene	Oregon
United States	Washington Radiologist Medical Group	Fremont	California
United States	Adventist Health Partners	Hinsdale	Illinois
United States	Presence Saint Joseph Medical Center	Joliet	Illinois
United States	Radiology Imaging Specialist of Lakeland	Lakeland	Florida
United States	The Back Center	Melbourne	Florida
United States	Scoliosis & Spine Surgery Clinic of Memphis, PLLC	Memphis	Tennessee
United States	The West Clinic	Memphis	Tennessee
United States	Illinois Bone & Joint	Morton Grove	Illinois
United States	Sierra Regional Spine Institute	Reno	Nevada
United States	Sutter Health Sacramento Sierra Region	Sacramento	California
United States	Advanced Diagnostic Imaging, PC	Saginaw	Michigan
United States	Alta Orthopaedic Medical Group	Santa Barbara	California
United States	Consulting Orthopaedic Associates, Inc	Sylvania	Ohio
United States	Torrance Memorial Medical Center	Torrance	California
United States	Beaumont Health System	Troy	Michigan
United States	James R. Webb, P.C.	Tulsa	Oklahoma
United States	Premier Radiology	Tupelo	Mississippi

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Spinal and Biologics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in back function by Oswestry Disability Index		3 months	No
Primary	Change from baseline in back pain by Numerical Rating Scale		3 months	No
Primary	Change from baseline in quality of life by SF-36v2 Physical Component Summary		3 months	No
Primary	Change from baseline in quality of life by the EQ-5D		3 months	No